DAWN Earnings

DAWN reported its FY2025Q4 earnings on 2026-02-26, showcasing a revenue of 0.00 against an estimate of 42.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.15 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following DAWN's FY2025Q4 earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, DAWN's stock price tends to shift by an average of -1.53% in the 10 days leading up to earnings and -3.64% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate DAWN’s annual revenue to reach 44.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 2.05% and EPS estimates Revise Upward by 2.93% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between DAWN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 2.05%, while EPS estimates moved Revise Upward by 2.93% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DAWN's stock price typically moves by -1.53% in the 10 days before its earnings and -3.64% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 44.00M.

The earnings call shows strong financial performance with a 15% QoQ revenue increase and an 89% YoY growth, alongside strategic product developments and expansion plans. Despite some uncertainties in data maturity and profitability guidance, the company's solid cash position and reduced operating expenses highlight financial discipline. The Q&A session reflects management's cautious optimism, with positive updates on trial progress and market expansion. Given the market cap of approximately $1.2 billion, the stock is likely to react positively, with potential gains in the 2% to 8% range over the next two weeks.